HLB Innovation has appointed Jin Yang-gon, Chairman of the Board of Directors of HLB Group, as its new CEO.


Jin Yang-gon, Chairman of HLB Group, Appointed CEO of HLB Innovation View original image


On July 1, HLB Innovation held a board meeting and approved the agenda to appoint Chairman Jin as the new CEO. As a result, CEO Jin will oversee all company operations and lead the semiconductor business, while CEO Brian Kim will continue to be responsible for the bio business, maintaining a dual CEO system.


The company explained that Chairman Jin will directly take charge of overall management in order to more rapidly implement its growth strategy centered on both semiconductors and bio, as well as to establish a prompt decision-making system for key management issues. The previous CEO resigned from the position for personal reasons.


HLB Innovation is currently experiencing significant growth momentum in both its semiconductor and bio businesses. In the semiconductor segment, the company has strengthened its business competitiveness through ongoing facility investments aimed at streamlining production processes and expanding production capacity (CAPA). It is also proactively responding to the recovery of global demand by advancing process automation and upgrading production capabilities.


In the bio segment, the company is developing its next-generation CAR-T platform as a core growth engine for mid- to long-term corporate value enhancement, centered on its U.S. subsidiary, Verismo. Verismo is currently conducting Phase 1 clinical trials for 'SynKIR-110,' a solid tumor therapy, and 'SynKIR-310,' a blood cancer therapy, based on its proprietary KIR-CAR platform. In the first half of this year, the interim results of SynKIR-110's clinical trial drew industry attention by demonstrating excellent safety and initial antitumor activity and cell persistence signals, with no dose-limiting toxicity (DLT), severe cytokine release syndrome (CRS), or neurotoxicity (ICANS) observed. In the second half of the year, interim data from SynKIR-310’s Phase 1 trial is scheduled to be released, which is expected to further validate the competitiveness of Verismo’s platform.



A representative from HLB Innovation stated, "As both the semiconductor and bio businesses enter a critical growth phase, Chairman Jin has taken on the CEO position to strengthen overall execution and maximize business performance through swift decision-making," adding, "We will accelerate the growth strategies of both major businesses to continuously enhance corporate value."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing